An exploratory, randomized, double blind, placebo controlled, parallel groups Phase II clinical trial to evaluate the efficacy and safety of E-52862 (400 mg) by oral route, in patients with postherpetic neuralgia (PHN).
Phase of Trial: Phase II
Latest Information Update: 23 May 2014
At a glance
- Drugs E 52862 (Primary)
- Indications Postherpetic neuralgia
- Focus Therapeutic Use
- Sponsors Laboratorios Dr. Esteve
- 26 Mar 2014 Trial status changed to discontinued as reported by European Clinical Trials Database.
- 27 Aug 2012 New trial record